Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
BTMD vs GDRX vs HIMS vs AMWL
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Equipment & Services
Medical - Healthcare Information Services
BTMD vs GDRX vs HIMS vs AMWL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Information Services | Medical - Equipment & Services | Medical - Healthcare Information Services |
| Market Cap | $92M | $973M | $6.63B | $129M |
| Revenue (TTM) | $188M | $788M | $2.35B | $182M |
| Net Income (TTM) | $16M | $29M | $128M | $-88M |
| Gross Margin | 70.1% | 81.0% | 69.7% | 38.7% |
| Operating Margin | 15.4% | 12.4% | 4.6% | -50.6% |
| Forward P/E | 2.8x | 9.0x | 51.5x | — |
| Total Debt | $110M | $60M | $1.12B | $5M |
| Cash & Equiv. | $24M | $262M | $229M | $182M |
BTMD vs GDRX vs HIMS vs AMWL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| biote Corp. (BTMD) | 100 | 20.8 | -79.2% |
| GoodRx Holdings, In… (GDRX) | 100 | 7.1 | -92.9% |
| Hims & Hers Health,… (HIMS) | 100 | 207.3 | +107.3% |
| American Well Corpo… (AMWL) | 100 | 2.5 | -97.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BTMD vs GDRX vs HIMS vs AMWL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BTMD carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 8.3% margin vs AMWL's -48.2%
- 2.3% yield; the other 3 pay no meaningful dividend
- 15.1% ROA vs AMWL's -25.1%, ROIC 11.3% vs -95.1%
GDRX is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.58
HIMS is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs BTMD's -79.2%
- 59.0% revenue growth vs BTMD's -2.5%
AMWL is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
- Beta 1.47, current ratio 3.37x
- Beta 1.47 vs HIMS's 2.40, lower leverage
- +14.3% vs HIMS's -51.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs BTMD's -2.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 8.3% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.47 vs HIMS's 2.40, lower leverage | |
| Dividends | 2.3% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +14.3% vs HIMS's -51.0% | |
| Efficiency (ROA) | 15.1% ROA vs AMWL's -25.1%, ROIC 11.3% vs -95.1% |
BTMD vs GDRX vs HIMS vs AMWL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BTMD vs GDRX vs HIMS vs AMWL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BTMD leads in 1 of 6 categories
HIMS leads 1 • AMWL leads 1 • GDRX leads 1 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BTMD and GDRX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS is the larger business by revenue, generating $2.3B annually — 12.9x AMWL's $182M. BTMD is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $188M | $788M | $2.3B | $182M |
| EBITDAEarnings before interest/tax | $32M | $184M | $164M | -$59M |
| Net IncomeAfter-tax profit | $16M | $29M | $128M | -$88M |
| Free Cash FlowCash after capex | $29M | $132M | $73M | -$42M |
| Gross MarginGross profit ÷ Revenue | +70.1% | +81.0% | +69.7% | +38.7% |
| Operating MarginEBIT ÷ Revenue | +15.4% | +12.4% | +4.6% | -50.6% |
| Net MarginNet income ÷ Revenue | +8.3% | +3.7% | +5.5% | -48.2% |
| FCF MarginFCF ÷ Revenue | +15.2% | +16.7% | +3.1% | -22.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -8.3% | -4.4% | +28.4% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -83.8% | -1.3% | -27.3% | +44.5% |
Valuation Metrics
Evenly matched — BTMD and GDRX and AMWL each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 2.8x trailing earnings, BTMD trades at a 94% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $92M | $973M | $6.6B | $129M |
| Enterprise ValueMkt cap + debt − cash | $178M | $771M | $7.5B | -$48M |
| Trailing P/EPrice ÷ TTM EPS | 2.82x | 33.29x | 50.32x | -1.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.98x | 51.51x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 4.54x | 4.01x | 42.68x | — |
| Price / SalesMarket cap ÷ Revenue | 0.48x | 1.22x | 2.82x | 0.52x |
| Price / BookPrice ÷ Book value/share | — | 1.65x | 12.25x | 0.50x |
| Price / FCFMarket cap ÷ FCF | 3.05x | 5.92x | 89.61x | — |
Profitability & Efficiency
BTMD leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), BTMD scores 6/9 vs HIMS's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +4.8% | +23.7% | -33.5% |
| ROA (TTM)Return on assets | +15.1% | +1.9% | +6.0% | -25.1% |
| ROICReturn on invested capital | +11.3% | +13.0% | +10.7% | -95.1% |
| ROCEReturn on capital employed | +53.3% | +8.8% | +10.9% | -36.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.10x | 2.07x | 0.02x |
| Net DebtTotal debt minus cash | $86M | -$202M | $892M | -$178M |
| Cash & Equiv.Liquid assets | $24M | $262M | $229M | $182M |
| Total DebtShort + long-term debt | $110M | $60M | $1.1B | $5M |
| Interest CoverageEBIT ÷ Interest expense | 3.02x | 3.61x | — | -239.18x |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs AMWL's -42.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.4% | +3.3% | -23.2% | +59.8% |
| 1-Year ReturnPast 12 months | -37.4% | -25.1% | -51.0% | +14.3% |
| 3-Year ReturnCumulative with dividends | -69.7% | -38.4% | +116.6% | -80.7% |
| 5-Year ReturnCumulative with dividends | -79.1% | -91.8% | +137.6% | -97.2% |
| 10-Year ReturnCumulative with dividends | -79.2% | -94.4% | +161.9% | -98.3% |
| CAGR (3Y)Annualised 3-year return | -32.8% | -14.9% | +29.4% | -42.2% |
Risk & Volatility
AMWL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMWL is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 1.58x | 2.40x | 1.47x |
| 52-Week HighHighest price in past year | $4.75 | $5.81 | $70.43 | $9.15 |
| 52-Week LowLowest price in past year | $1.27 | $1.77 | $13.74 | $3.71 |
| % of 52W HighCurrent price vs 52-week peak | +44.0% | +48.9% | +36.4% | +84.7% |
| RSI (14)Momentum oscillator 0–100 | 62.2 | 66.1 | 54.5 | 67.1 |
| Avg Volume (50D)Average daily shares traded | 265K | 2.3M | 34.9M | 59K |
Analyst Outlook
GDRX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: GDRX as "Hold", HIMS as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 12.3% for GDRX (target: $3). BTMD is the only dividend payer here at 2.25% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | — |
| Price TargetConsensus 12-month target | — | $3.19 | $29.67 | — |
| # AnalystsCovering analysts | — | 24 | 19 | — |
| Dividend YieldAnnual dividend ÷ price | +2.3% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | — | — |
| Dividend / ShareAnnual DPS | $0.05 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.7% | +21.3% | +1.4% | +0.0% |
BTMD leads in 1 of 6 categories (Profitability & Efficiency). HIMS leads in 1 (Total Returns). 2 tied.
BTMD vs GDRX vs HIMS vs AMWL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BTMD or GDRX or HIMS or AMWL a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 5% for biote Corp. (BTMD). biote Corp. (BTMD) offers the better valuation at 2. 8x trailing P/E, making it the more compelling value choice. Analysts rate GoodRx Holdings, Inc. (GDRX) a "Hold" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BTMD or GDRX or HIMS or AMWL?
On trailing P/E, biote Corp.
(BTMD) is the cheapest at 2. 8x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BTMD or GDRX or HIMS or AMWL?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BTMD or GDRX or HIMS or AMWL?
By beta (market sensitivity over 5 years), American Well Corporation (AMWL) is the lower-risk stock at 1.
47β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 64% more volatile than AMWL relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BTMD or GDRX or HIMS or AMWL?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -2. 5% for biote Corp. (BTMD). On earnings-per-share growth, the picture is similar: biote Corp. grew EPS 703. 5% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BTMD or GDRX or HIMS or AMWL?
biote Corp.
(BTMD) is the more profitable company, earning 14. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 14. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTMD leads at 18. 5% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BTMD or GDRX or HIMS or AMWL more undervalued right now?
On forward earnings alone, GoodRx Holdings, Inc.
(GDRX) trades at 9. 0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 42. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.
08Which pays a better dividend — BTMD or GDRX or HIMS or AMWL?
In this comparison, BTMD (2.
3% yield) pays a dividend. GDRX, HIMS, AMWL do not pay a meaningful dividend and should not be held primarily for income.
09Is BTMD or GDRX or HIMS or AMWL better for a retirement portfolio?
For long-horizon retirement investors, biote Corp.
(BTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 3% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BTMD: -79. 2%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BTMD and GDRX and HIMS and AMWL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BTMD is a small-cap deep-value stock; GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; AMWL is a small-cap quality compounder stock. BTMD pays a dividend while GDRX, HIMS, AMWL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.